SEI Investments’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $203K | Buy |
+45,039
| New | +$235K | ﹤0.01% | 2970 |
|
|
2025
Q2 | – | Sell |
-2,416,492
| Closed | -$21.4M | – | 2872 |
|
|
2025
Q1 | $21.4M | Sell |
2,416,492
-110,269
| -4% | -$1.32M | 0.03% | 646 |
|
|
2024
Q4 | $34.6M | Buy |
2,526,761
+174,770
| +7% | +$3.22M | 0.04% | 435 |
|
|
2024
Q3 | $64.4M | Sell |
2,351,991
-65,201
| -3% | -$1.77M | 0.08% | 260 |
|
|
2024
Q2 | $59.1M | Buy |
2,417,192
+124,007
| +5% | +$2.72M | 0.08% | 253 |
|
|
2024
Q1 | $48.9M | Buy |
2,293,185
+131,751
| +6% | +$2.83M | 0.07% | 293 |
|
|
2023
Q4 | $41.4M | Buy |
2,161,434
+638,147
| +42% | +$11M | 0.07% | 320 |
|
|
2023
Q3 | $24.4M | Buy |
1,523,287
+140,528
| +10% | +$2.67M | 0.04% | 454 |
|
|
2023
Q2 | $32.1M | Buy |
1,382,759
+84,463
| +7% | +$1.84M | 0.06% | 373 |
|
|
2023
Q1 | $30.2M | Buy |
1,298,296
+85,662
| +7% | +$1.74M | 0.06% | 383 |
|
|
2022
Q4 | $17.6M | Buy |
1,212,634
+37,166
| +3% | +$693K | 0.04% | 502 |
|
|
2022
Q3 | $22.4M | Sell |
1,175,468
-3,196
| -0.3% | -$73.3K | 0.05% | 416 |
|
|
2022
Q2 | $21.4M | Buy |
1,178,664
+290,269
| +33% | +$6.03M | 0.05% | 430 |
|
|
2022
Q1 | $22.4M | Buy |
888,395
+90,449
| +11% | +$2.31M | 0.05% | 444 |
|
|
2021
Q4 | $22M | Buy |
797,946
+13,637
| +2% | +$395K | 0.04% | 454 |
|
|
2021
Q3 | $25.3M | Buy |
784,309
+748,127
| +2,068% | +$24.8M | 0.05% | 366 |
|
|
2021
Q2 | $1.11M | Buy |
36,182
+10,507
| +41% | +$304K | ﹤0.01% | 1774 |
|
|
2021
Q1 | $782K | Buy |
+25,675
| New | +$729K | ﹤0.01% | 1855 |
|
|
2020
Q1 | – | Sell |
-209,479
| Closed | -$5.7M | – | 2408 |
|
|
2019
Q4 | $5.7M | Sell |
209,479
-1,721
| -0.8% | -$47.3K | 0.02% | 856 |
|
|
2019
Q3 | $6.05M | Sell |
211,200
-29,436
| -12% | -$858K | 0.02% | 850 |
|
|
2019
Q2 | $6.69M | Buy |
240,636
+46,382
| +24% | +$1.31M | 0.02% | 788 |
|
|
2019
Q1 | $6.42M | Buy |
194,254
+128,625
| +196% | +$3.92M | 0.02% | 782 |
|
|
2018
Q4 | $2.44M | Buy |
65,629
+30,789
| +88% | +$1.11M | 0.01% | 1228 |
|
|
2018
Q3 | $1.59M | Buy |
34,840
+32,911
| +1,706% | +$1.46M | 0.01% | 1332 |
|
|
2018
Q2 | $72K | Buy |
1,929
+1,911
| +10,617% | +$64.5K | ﹤0.01% | 2387 |
|
|
2018
Q1 | $1K | Sell |
18
-704
| -98% | -$23.8K | ﹤0.01% | 3338 |
|
|
2017
Q4 | $25K | Sell |
722
-18,796
| -96% | -$634K | ﹤0.01% | 2536 |
|
|
2017
Q3 | $707K | Buy |
19,518
+19,420
| +19,816% | +$554K | ﹤0.01% | 1545 |
|
|
2017
Q2 | $3K | Hold |
98
| – | – | ﹤0.01% | 2817 |
|
|
2017
Q1 | $2K | Hold |
98
| – | – | ﹤0.01% | 2718 |
|
|
2016
Q4 | $2K | Sell |
98
-13,441
| -99% | -$243K | ﹤0.01% | 2727 |
|
|
2016
Q3 | $278K | Sell |
13,539
-85,967
| -86% | -$2.18M | ﹤0.01% | 1598 |
|
|
2016
Q2 | $3.04M | Sell |
99,506
-38,870
| -28% | -$1.35M | 0.02% | 839 |
|
|
2016
Q1 | $5.18M | Buy |
138,376
+15,140
| +12% | +$570K | 0.03% | 611 |
|
|
2015
Q4 | $5.32M | Sell |
123,236
-47,873
| -28% | -$2.02M | 0.03% | 630 |
|
|
2015
Q3 | $6.41M | Buy |
171,109
+101,198
| +145% | +$3.59M | 0.06% | 387 |
|
|
2015
Q2 | $2.38M | Buy |
69,911
+27,797
| +66% | +$945K | 0.02% | 691 |
|
|
2015
Q1 | $1.49M | Buy |
42,114
+41,931
| +22,913% | +$1.5M | 0.01% | 835 |
|
|
2014
Q4 | $6K | Buy |
+183
| New | +$6.49K | ﹤0.01% | 1932 |
|
Other funds holding MYGN
O
GCM
VCM
VPM
SEI Investments's MYGN Position: Q1 2026 in Review
SEI Investments opened a new position in Myriad Genetics (MYGN) in Q1 2026: 45,039 shares worth $203K. The stake represents ﹤0.01% of the portfolio and ranks #2970 among its holdings. This is a return to the name: SEI Investments previously reported a position in MYGN as recently as Q1 2025.
SEI Investments first reported a position in MYGN in Q4 2014 and has held it in 39 quarters since. The position peaked at $64.4M in Q3 2024. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.
- SEI Investments held 45,039 shares of Myriad Genetics worth $203K as of Q1 2026.
- Myriad Genetics was a new SEI Investments position in Q1 2026.
- Myriad Genetics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2970 holding.
- SEI Investments first reported a position in Myriad Genetics in Q4 2014 and has held it in 39 quarters since.
- SEI Investments's Myriad Genetics position peaked at $64.4M in Q3 2024.
- 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.
Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.